<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03315559</url>
  </required_header>
  <id_info>
    <org_study_id>206764</org_study_id>
    <secondary_id>2017-002347-16</secondary_id>
    <nct_id>NCT03315559</nct_id>
  </id_info>
  <brief_title>Absorption &amp; Elimination of Radiolabelled GSK2269557</brief_title>
  <official_title>An Open-label Study in Healthy Male Subjects, to Determine the Excretion Balance and Pharmacokinetics of [14C]-GSK2269557, Administered as a Single Intravenous Microtracer (Concomitant With an Inhaled Non-radiolabelled Dose) and a Single Oral Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK2269557 is being developed as an anti-inflammatory agent for the treatment of chronic
      obstructive pulmonary disease (COPD) and other inflammatory lung diseases such as asthma.
      This study is designed to investigate the recovery, excretion, and pharmacokinetics (PK) of
      (14 Carbon [C])-GSK2269557 administered as a single intravenous (IV) dose (concomitant with
      an inhaled non-radiolabelled dose) and as a single oral dose in 6 healthy male subjects.
      Subjects will receive [14C] radiolabelled GSK2269557 administered as IV infusion, with a
      nonradiolabelled dose of GSK2269557 via dry powder inhaler (DPI) in treatment period 1 and a
      single dose of [14C]-GSK2269557, administered as an oral solution in treatment period 2.
      There will be a washout period of at least 14 days after inhaled and IV dosing before
      subjects takes part in treatment period 2. The IV microtracer dose of GSK2269557 will be
      administered concomitant to an inhaled non-radiolabelled dose to ensure that the
      pharmacokinetics represent a clinically relevant dose. The total study duration will be up to
      11 weeks, including a screening visit, 2 treatment periods and a follow-up visit.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 14, 2017</start_date>
  <completion_date type="Actual">December 22, 2017</completion_date>
  <primary_completion_date type="Actual">December 22, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This will be a 2-period, single-sequence crossover study. Subjects will receive IV and inhaled doses of GSK2269557 in treatment period 1 and oral dose of GSK2269557 in treatment period 2.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This will be an open-label study. Hence, masking will not be provided to the subjects.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Concentration-time Curve (AUC) From Time 0 (Pre-dose) to Infinite Time (0 to Inf) and AUC From Time 0 (Pre-dose) to Last Time of Quantifiable Concentration (0 to t) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 1</measure>
    <time_frame>Pre-dose and at 0 hour (post inhalation and pre-IV infusion), at the end of infusion and at 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours after the start of infusion</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. Pharmacokinetic (PK) Population comprised of participants in the APE Population who received at least one dose of study treatment and for whom a PK sample was obtained and analyzed. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC From Time Zero (Pre-dose) Extrapolated to Infinite Time (0 to Inf) and AUC From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (0 to t) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 2</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96 and 168 h post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. Only those participants available at the specified time points were analyzed represented by n=X in the category titles. NA indicates that data is not available as single participant was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 1</measure>
    <time_frame>Pre-dose and at 0 hour (post inhalation and pre-IV infusion), at the end of infusion and at 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours after the start of infusion</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 2</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96 and 168 h post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Occurrence of Cmax (Tmax) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 1</measure>
    <time_frame>Pre-dose and at 0 hour (post inhalation and pre-IV infusion), at the end of infusion and at 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours after the start of infusion</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 2</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96 and 168 h post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Phase Half-life (t1/2) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 1</measure>
    <time_frame>Pre-dose and at 0 hour (post inhalation and pre-IV infusion), at the end of infusion and at 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours after the start of infusion</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Phase Half-life (t1/2) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 2</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96 and 168 h post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. NA indicates that data is not available as single participant was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary and Faecal Cumulative Excretion as a Percentage of the Total Radioactive Dose Administered Over Time for Treatment Period 1</measure>
    <time_frame>Up to 168 hours</time_frame>
    <description>Urine samples and fecal samples were collected to measure total radiolabeled drug-related material excreted in urine and feces respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary and Fecal Cumulative Excretion as a Percentage of the Total Radioactive Dose Administered Over Time for Treatment Period 2</measure>
    <time_frame>Up to 336 hours</time_frame>
    <description>Urine samples and fecal samples were collected to measure total radiolabeled drug-related material excreted in urine and feces respectively. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC (0 to Inf) and AUC (0 to t) of Parent GSK2269557 and [14C]-GSK2269557 in Plasma for Treatment Period 1</measure>
    <time_frame>Pre-dose and at 0 hour (post inhalation and pre-IV infusion), at the end of infusion and at 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours after the start of infusion</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS, whereas GSK2269557 describes the parent GSK2269557 concentration derived via LC/MS. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0 to Inf) and AUC (0 to t) of [14C]-GSK2269557 in Plasma for Treatment Period 2</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96 and 168 h post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. Only those participants with data available at the specified time points were analyzed represented by n=X in the category titles. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Parent GSK2269557 and [14C]-GSK2269557 in Plasma for Treatment Period 1</measure>
    <time_frame>Pre-dose and at 0 hour (post inhalation and pre-IV infusion), at the end of infusion and at 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours after the start of infusion</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS, whereas GSK2269557 describes the parent GSK2269557 concentration derived via LC/MS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of [14C]-GSK2269557 in Plasma for Treatment Period 2</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96 and 168 h post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Parent GSK2269557 and [14C]-GSK2269557 in Plasma for Treatment Period 1</measure>
    <time_frame>Pre-dose and at 0 hour (post inhalation and pre-IV infusion), at the end of infusion and at 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours after the start of infusion</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS, whereas GSK2269557 describes the parent GSK2269557 concentration derived via LC/MS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of [14C]-GSK2269557 in Plasma for Treatment Period 2</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96 and 168 h post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Parent GSK2269557 and [14C]-GSK2269557 in Plasma for Treatment Period 1</measure>
    <time_frame>Pre-dose and at 0 hour (post inhalation and pre-IV infusion), at the end of infusion and at 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours after the start of infusion</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS, whereas GSK2269557 describes the parent GSK2269557 concentration derived via LC/MS. Only those participants available at the indicated time points were analyzed represented by n=X in the category titles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of [14C]-GSK2269557 in Plasma for Treatment Period 2</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96 and 168 h post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution of Parent [14C]-GSK2269557 After IV Dose Only in Plasma</measure>
    <time_frame>Pre-dose and at 0 hour (post inhalation and pre-IV infusion), at the end of infusion and at 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours after the start of infusion</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of Parent [14C]-GSK2269557 After IV Dose Only in Plasma</measure>
    <time_frame>Pre-dose and at 0 hour (post inhalation and pre-IV infusion), at the end of infusion and at 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours after the start of infusion</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhaled Absolute Bioavailability (F) for Treatment Period 1</measure>
    <time_frame>Pre-dose and at 0 hour (post inhalation and pre-IV infusion), at the end of infusion and at 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours after the start of infusion</time_frame>
    <description>Absolute bioavailability (F) was estimated for the inhaled doses for each participant and is reported. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Absolute Bioavailability (F) for Treatment Period 2</measure>
    <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96 and 168 h post-dose</time_frame>
    <description>Absolute bioavailability (F) was estimated for the oral doses for each participant and is reported. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)</measure>
    <time_frame>Up to 11 weeks</time_frame>
    <description>AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with use of a medicinal product (MP), whether or not considered related to MP. AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with use of MP. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant or all events of possible drug induced liver injury with hyperbilirubinemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hematology Parameters of Potential Clinical Concern</measure>
    <time_frame>Up to 11 weeks</time_frame>
    <description>Hematology parameters included basophils, eosinophils, erythrocytes, monocytes, hematocrit, hemoglobin, lymphocytes, neutrophil count, platelet count and white blood cells. Number of participants with hematology parameters of potential clinical concern are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Chemistry Parameters of Potential Clinical Concern</measure>
    <time_frame>Up to 11 weeks</time_frame>
    <description>Clinical chemistry parameters included alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, chloride, cholesterol, gamma glutamyl transferase, globulin, protein, triglycerides, urate, albumin, calcium, creatinine, glucose, phosphorous, potassium, urea and sodium. Number of participants with clinical chemistry parameters of potential clinical concern are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Urinalysis Findings</measure>
    <time_frame>Up to 168 hours</time_frame>
    <description>Urine samples were collected to detect the presence of bilirubin, glucose, ketones, leukocyte esterase, nitrite, occult blood, protein and urobilinogen. Urinalysis also included measurement of specific gravity and pH. Number of participants with clinically significant urinalysis findings are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Electrocardiogram Findings of Clinical Significance</measure>
    <time_frame>Up to 11 weeks</time_frame>
    <description>Twelve-lead electrocardiogram was measured in a supine or semi-supine position after 5 minutes rest. Number of participants with electrocardiogram findings of clinical significance are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Vital Signs of Potential Clinical Concern</measure>
    <time_frame>Up to 11 weeks</time_frame>
    <description>Vital signs were measured in a supine or semi-supine position after 5 minutes rest and included temperature, systolic and diastolic blood pressure and pulse and respiratory rate. Number of participants with vital signs of potential clinical concern are reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Subjects receiving GSK2269557 in treatment period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive IV infusion of [14C] radiolabelled GSK2269557 with a single dose of 10 micrograms (µg) administered as single microtracer, concomitantly with an inhaled nonradiolabelled 1000 µg dose of GSK2269557. There will be a washout of at least 14 days after inhaled and IV dosing before subjects receive treatment 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving GSK2269557 in treatment period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive [14C]-GSK2269557 with a single dose of 800 µg, administered as an oral solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-GSK2269557 IV infusion</intervention_name>
    <description>The [14C]-GSK2269557 solution will be available in dosing strength of 10 µg, administered as single dose IV infusion over 15 minutes. It will be prepared by dissolving a hemisuccinate salt (GSK2269557T) in normal saline.</description>
    <arm_group_label>Subjects receiving GSK2269557 in treatment period 1</arm_group_label>
    <arm_group_label>Subjects receiving GSK2269557 in treatment period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2269557 via DPI</intervention_name>
    <description>GSK2269557 DPI will be available with dosing strength of 1000 µg, administered as oral inhalation intended to inhale twice. It will be prepared by blending GSK2269557 hemisuccinate salt (GSK2269557H) with lactose and magnesium stearate.</description>
    <arm_group_label>Subjects receiving GSK2269557 in treatment period 1</arm_group_label>
    <arm_group_label>Subjects receiving GSK2269557 in treatment period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-GSK2269557 oral solution</intervention_name>
    <description>The [14C]-GSK2269557 solution will be available with dosing strength of 800 µg, administered as single dose orally. It will be prepared by dissolving [14C]-GSK2269557 hemisuccinate salt (GSK2269557T) in water.</description>
    <arm_group_label>Subjects receiving GSK2269557 in treatment period 1</arm_group_label>
    <arm_group_label>Subjects receiving GSK2269557 in treatment period 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be 30 to 55 years of age inclusive, at the time of signing the informed
             consent.

          -  Subjects who are overtly healthy as determined by the investigator or medically
             qualified designee based on a medical evaluation including medical history, physical
             examination, vital signs, laboratory tests, and cardiac monitoring; A subject with a
             clinical abnormality or laboratory parameter(s) which is/are not specifically listed
             in the inclusion or exclusion criteria, outside the reference range for the population
             being studied may be included only if the investigator agrees and documents that the
             finding is unlikely to introduce additional risk factors and will not interfere with
             the study procedures.

          -  A history of regular bowel movements (averaging one or more bowel movements per day).

          -  Body weight &gt;= 50 kilograms (Kg) and body mass index (BMI) within the range 19.0-31.0
             kg per meter square (kg/m^2) (inclusive).

          -  Male subjects will be included.

          -  Subjects with female partners of childbearing potential must agree to use
             contraception during the treatment period, from the time of first dose of study
             medication until follow-up, and refrain from donating sperm during this period.

          -  Capable of giving signed informed consent.

        Exclusion Criteria:

          -  Alanine aminotransferase (ALT) &gt; 1.5x Upper limit of normal (ULN).

          -  Bilirubin &gt; 1.5xULN (isolated bilirubin &gt; 1.5xULN is acceptable if bilirubin is
             fractionated and direct bilirubin &lt; 35%).

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  Mean QT duration corrected for heart rate by Fridericia's formula (QTCF) &gt; 450
             milliseconds (msec).

          -  Any clinically relevant abnormality identified at the screening medical assessment
             (physical examination/medical history), clinical laboratory tests, or 12-lead ECG.

          -  A pre-existing condition(s) interfering with normal gastrointestinal (GI) anatomy or
             motility, including constipation, malabsorption or other GI dysfunction which may
             interfere with the absorption, distribution, metabolism or elimination of the study
             drug. Subjects with a history of cholecystectomy must be excluded.

          -  At screening, a supine or semi-supine BP that is persistently higher (triplicate
             measurements at least 2 minutes apart than 140/90 millimeters of mercury (mmHg).

          -  At screening, a supine or semi-supine mean heart rate (HR) outside the range 40-90
             beats per minute (BPM).

          -  Subject is mentally or legally incapacitated.

          -  A history of respiratory disease (example given [e.g.] history of asthma) in the last
             10 years.

          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a
             potential enzyme inducer) or 5 half-lives (whichever is longer) before the first dose
             of study medication, unless in the opinion of the investigator and GlaxoSmithKline
             (GSK) Medical Monitor the medication will not interfere with the study procedures or
             compromise subject safety.

          -  Need of Paracetamol or Acetaminophen, at doses of &gt; 2 grams (g)/day. Other concomitant
             medication may be considered on a case by case basis by the GSK Medical Monitor.

          -  The subject has participated in a clinical trial and has received an investigational
             product (IP) within 3 months before their first dose in the current study.

          -  Participation in a clinical trial involving administration of 14C-labelled compound(s)
             within the last 12 months. A subject's previous effective dose will be reviewed by the
             medical investigator to ensure there is no risk of contamination/carryover into the
             current study.

          -  Presence of hepatitis B surface antigen (HBsAg), or positive hepatitis C antibody test
             result at screening.

          -  Positive Hepatitis C ribonucleic acid (RNA) test result at screening or within 3
             months prior to first dose of study treatment.

          -  A positive test for Human Immunodeficiency Virus (HIV) antibody.

          -  A positive pre-study drug/alcohol screen.

          -  Exposure to more than four new chemical entities within 12 months before the subject's
             first dose.

          -  Subjects have received a total body radiation dose of greater than 5.0 micro sievert
             (mSv) (upper limit of World Health Organization [WHO] category II) or exposure to
             significant radiation (e.g. serial x-ray or computed tomography [CT] scans, barium
             meal etc) in the 12 months before this study.

          -  An occupation which requires monitoring for radiation exposure, nuclear medicine
             procedures or excessive x-rays within the past 12 months.

          -  Participation in the study would result in donation of blood or blood products in
             excess of 500 milliliters (mL) within a 90 day period.

          -  Unwillingness or known inability to follow the procedures outlined in the protocol,
             including the use of the Enterotest capsule.

          -  History of regular alcohol consumption within 6 months of the study, defined as an
             average weekly intake of &gt;21 units. One unit is equivalent to 8 g of alcohol: a
             halfpint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure
             of spirits.

          -  Urinary cotinine levels indicative of smoking; current smoker; or ex-smokers who gave
             up less than 6 months ago or who have a history of more than 10 pack-years. Pack-years
             = cigarettes per day x number of years smoked/20
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>This study will include 6 healthy male subjects.</gender_description>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Harrell AW, Wilson R, Man YL, Riddell K, Jarvis E, Young G, Chambers R, Crossman L, Georgiou A, Pereira A, Kenworthy D, Beaumont C, Marotti M, Wilkes D, Hessel EM, Fahy WA. An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects. Drug Metab Dispos. 2019 Dec;47(12):1457-1468. doi: 10.1124/dmd.119.088344. Epub 2019 Oct 24.</citation>
    <PMID>31649125</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <results_first_submitted>December 10, 2018</results_first_submitted>
  <results_first_submitted_qc>December 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 20, 2019</results_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK2269557</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Radiolabel</keyword>
  <keyword>Healthy</keyword>
  <keyword>Excretion</keyword>
  <keyword>Bioavailability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD is available via the Clinical Study Data Request site (click on the link provided below)</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>https://clinicalstudydatarequest.com/Posting.aspx?ID=20278</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT03315559/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT03315559/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at a single center in the United Kingdom from 14-November-2017 to 22-December-2017.</recruitment_details>
      <pre_assignment_details>A total of 7 participants were screened, of which 1 participant was a reserve participant and was not used. The remaining 6 participants were enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>Participants received intravenous (IV) infusion of [14C] radiolabeled GSK2269557 along with a single dose of 10 micrograms (µg) administered as single microtracer, concomitantly with an inhaled non-radiolabeled 1000 µg dose of GSK2269557 in Treatment Period 1. There was a washout of at least 14 days. Participants received [14C]-GSK2269557 with a single dose of 800 µg, administered as an oral solution in Treatment Period 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1 (8 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 2 (15 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Participants received intravenous (IV) infusion of [14C] radiolabeled GSK2269557 along with a single dose of 10 micrograms (µg) administered as single microtracer, concomitantly with an inhaled non-radiolabeled 1000 µg dose of GSK2269557 in Treatment Period 1. There was a washout of at least 14 days. Participants received [14C]-GSK2269557 with a single dose of 800 µg, administered as an oral solution in Treatment Period 2.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Safety Population comprised of all participants in the All Participants Enrolled (APE) Population (All participants for whom a record exists on the study database; included both screened and unscreened participants but signed the informed consent form) who received at least one dose of study treatment.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.3" spread="10.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Count of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American/African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under Concentration-time Curve (AUC) From Time 0 (Pre-dose) to Infinite Time (0 to Inf) and AUC From Time 0 (Pre-dose) to Last Time of Quantifiable Concentration (0 to t) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 1</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. Pharmacokinetic (PK) Population comprised of participants in the APE Population who received at least one dose of study treatment and for whom a PK sample was obtained and analyzed. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.</description>
        <time_frame>Pre-dose and at 0 hour (post inhalation and pre-IV infusion), at the end of infusion and at 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours after the start of infusion</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Nemi IH + 14C-Nemi IV</title>
            <description>Participants received IV infusion of [14C] radiolabeled GSK2269557 as a single dose of 10 µg administered as single microtracer, concomitantly with an inhaled non-radiolabeled 1000 µg dose of GSK2269557.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Concentration-time Curve (AUC) From Time 0 (Pre-dose) to Infinite Time (0 to Inf) and AUC From Time 0 (Pre-dose) to Last Time of Quantifiable Concentration (0 to t) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 1</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. Pharmacokinetic (PK) Population comprised of participants in the APE Population who received at least one dose of study treatment and for whom a PK sample was obtained and analyzed. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.</description>
          <population>PK Population.</population>
          <units>Hour*picogram Equivalent per millilitre</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC (0 to inf), n=3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="812.8550" spread="8.17885"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0 to t), n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="770.3316" spread="17.70272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC From Time Zero (Pre-dose) Extrapolated to Infinite Time (0 to Inf) and AUC From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (0 to t) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 2</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. Only those participants available at the specified time points were analyzed represented by n=X in the category titles. NA indicates that data is not available as single participant was analyzed.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96 and 168 h post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>14C-Nemi Oral</title>
            <description>Participants received [14C]-GSK2269557 as a single dose of 800 µg, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC From Time Zero (Pre-dose) Extrapolated to Infinite Time (0 to Inf) and AUC From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (0 to t) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 2</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. Only those participants available at the specified time points were analyzed represented by n=X in the category titles. NA indicates that data is not available as single participant was analyzed.</description>
          <population>PK Population.</population>
          <units>Hour*picogram Equivalent per millilitre</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC (0 to inf), n=1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34749.40" spread="NA">NA indicates that data is not available as single participant was analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0 to t), n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31730.13" spread="35.715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Concentration (Cmax) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 1</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis.</description>
        <time_frame>Pre-dose and at 0 hour (post inhalation and pre-IV infusion), at the end of infusion and at 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours after the start of infusion</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Nemi IH + 14C-Nemi IV</title>
            <description>Participants received IV infusion of [14C] radiolabeled GSK2269557 as a single dose of 10 µg administered as single microtracer, concomitantly with an inhaled non-radiolabeled 1000 µg dose of GSK2269557.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 1</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis.</description>
          <population>PK Population.</population>
          <units>Picogram Equivalent per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204.4057" spread="52.32698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 2</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96 and 168 h post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>14C-Nemi Oral</title>
            <description>Participants received [14C]-GSK2269557 as a single dose of 800 µg, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 2</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis.</description>
          <population>PK Population.</population>
          <units>Picogram Equivalent per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="703.5192" spread="24.43331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Occurrence of Cmax (Tmax) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 1</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis.</description>
        <time_frame>Pre-dose and at 0 hour (post inhalation and pre-IV infusion), at the end of infusion and at 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours after the start of infusion</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Nemi IH + 14C-Nemi IV</title>
            <description>Participants received IV infusion of [14C] radiolabeled GSK2269557 as a single dose of 10 µg administered as single microtracer, concomitantly with an inhaled non-radiolabeled 1000 µg dose of GSK2269557.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Occurrence of Cmax (Tmax) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 1</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis.</description>
          <population>PK Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2333" lower_limit="0.2333" upper_limit="0.2333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 2</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96 and 168 h post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>14C-Nemi Oral</title>
            <description>Participants received [14C]-GSK2269557 as a single dose of 800 µg, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 2</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis.</description>
          <population>PK Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0000" lower_limit="2.000" upper_limit="8.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Phase Half-life (t1/2) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 1</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis.</description>
        <time_frame>Pre-dose and at 0 hour (post inhalation and pre-IV infusion), at the end of infusion and at 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours after the start of infusion</time_frame>
        <population>PK Population. Only those participants available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nemi IH + 14C-Nemi IV</title>
            <description>Participants received IV infusion of [14C] radiolabeled GSK2269557 as a single dose of 10 µg administered as single microtracer, concomitantly with an inhaled non-radiolabeled 1000 µg dose of GSK2269557.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Phase Half-life (t1/2) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 1</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis.</description>
          <population>PK Population. Only those participants available at the indicated time points were analyzed.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9152" spread="7.69827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Phase Half-life (t1/2) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 2</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. NA indicates that data is not available as single participant was analyzed.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96 and 168 h post-dose</time_frame>
        <population>PK Population. Only those participants available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>14C-Nemi Oral</title>
            <description>Participants received [14C]-GSK2269557 as a single dose of 800 µg, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Phase Half-life (t1/2) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 2</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. NA indicates that data is not available as single participant was analyzed.</description>
          <population>PK Population. Only those participants available at the indicated time points were analyzed.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6279" spread="NA">NA indicates that data is not available as single participant was analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urinary and Faecal Cumulative Excretion as a Percentage of the Total Radioactive Dose Administered Over Time for Treatment Period 1</title>
        <description>Urine samples and fecal samples were collected to measure total radiolabeled drug-related material excreted in urine and feces respectively.</description>
        <time_frame>Up to 168 hours</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Nemi IH + 14C-Nemi IV</title>
            <description>Participants received IV infusion of [14C] radiolabeled GSK2269557 as a single dose of 10 µg administered as single microtracer, concomitantly with an inhaled non-radiolabeled 1000 µg dose of GSK2269557.</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary and Faecal Cumulative Excretion as a Percentage of the Total Radioactive Dose Administered Over Time for Treatment Period 1</title>
          <description>Urine samples and fecal samples were collected to measure total radiolabeled drug-related material excreted in urine and feces respectively.</description>
          <population>PK Population.</population>
          <units>Percentage of dose excreted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fe Feces, 0 to 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3961" spread="0.83271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Feces, 24 to 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1998" spread="3.77158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Feces, 48 to 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1265" spread="12.97670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Feces, 72 to 96 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0481" spread="18.22334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Feces, 96 to 120 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7465" spread="19.02044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Feces, 120 to 144 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2398" spread="14.63248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Feces, 144 to 168 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.6981" spread="15.46780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 0 to 6 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1567" spread="0.83754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 6 to 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1183" spread="1.53825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 24 to 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6850" spread="2.04159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 48 to 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3483" spread="2.26387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 72 to 96 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7150" spread="2.46640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 96 to 120 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6400" spread="2.52790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 120 to 144 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3607" spread="2.56693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 144 to 168 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9205" spread="2.57056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Total (Urine+Feces), 0 to 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5145" spread="1.30554"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Total (Urine+Feces), 24 to 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8848" spread="3.03062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Total (Urine+Feces), 48 to 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4748" spread="13.02973"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Total (Urine+Feces), 72 to 96 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7631" spread="18.40877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Total (Urine+Feces), 96 to 120 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3865" spread="19.01459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Total (Urine+Feces), 120 to 144 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.6005" spread="14.46954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Total (Urine+Feces), 144 to 168 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6186" spread="15.25339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urinary and Fecal Cumulative Excretion as a Percentage of the Total Radioactive Dose Administered Over Time for Treatment Period 2</title>
        <description>Urine samples and fecal samples were collected to measure total radiolabeled drug-related material excreted in urine and feces respectively. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.</description>
        <time_frame>Up to 336 hours</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>14C-Nemi Oral</title>
            <description>Participants received [14C]-GSK2269557 as a single dose of 800 µg, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary and Fecal Cumulative Excretion as a Percentage of the Total Radioactive Dose Administered Over Time for Treatment Period 2</title>
          <description>Urine samples and fecal samples were collected to measure total radiolabeled drug-related material excreted in urine and feces respectively. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.</description>
          <population>PK Population.</population>
          <units>Percentage of dose excreted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fe Feces, 0 to 24 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.81330" spread="7.16484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Feces, 24 to 48 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6367" spread="21.64607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Feces, 48 to 72 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9583" spread="28.48392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Feces, 72 to 96 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8217" spread="29.60581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Feces, 96 to 120 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7617" spread="18.24192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Feces, 120 to 144 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.1667" spread="19.65337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Feces, 144 to 168 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4217" spread="6.66365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Feces, 168 to 192 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1117" spread="5.29605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Feces, 192 to 216 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.0917" spread="4.59090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Feces, 216 to 240 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5933" spread="4.12513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Feces, 240 to 264 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.7917" spread="3.82906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Feces, 264 to 288 hour; n=5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6820" spread="4.07492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Feces, 288 to 312 hour; n=3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.9500" spread="3.78747"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Feces, 312 to 336 hour; n=3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.1500" spread="3.57979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 0 to 6 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3867" spread="0.09668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 6 to 24 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7017" spread="0.42995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 24 to 48 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7183" spread="0.73249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 48 to 72 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4250" spread="0.89063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 72 to 96 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9600" spread="0.97980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 96 to 120 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3617" spread="1.02918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 120 to 144 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6717" spread="1.09549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 144 to 168 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9217" spread="1.12583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 168 to 192 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1383" spread="1.16426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 192 to 216 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2950" spread="1.16156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 216 to 240 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4700" spread="1.20854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 240 to 264 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5617" spread="1.24856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 264 to 288 hour; n=5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4760" spread="1.35858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 288 to 312 hour; n=3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7800" spread="1.43293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Urine, 312 to 336 hour; n=3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8133" spread="1.45590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Total (Urine+Feces), 0 to 24 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5150" spread="7.01205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Total (Urine+Feces), 24 to 48 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3550" spread="21.303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Total (Urine+Feces), 48 to 72 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3833" spread="28.28365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Total (Urine+Feces), 72 to 96 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.7817" spread="29.36619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Total (Urine+Feces), 96 to 120 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.1233" spread="17.8525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Total (Urine+Feces), 120 to 144 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8383" spread="19.24589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Total (Urine+Feces), 144 to 168 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3433" spread="6.27302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Total (Urine+Feces), 168 to 192 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2500" spread="4.74848"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Total (Urine+Feces), 192 to 216 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.3867" spread="3.98209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Total (Urine+Feces), 216 to 240 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.0633" spread="3.3933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Total (Urine+Feces), 240 to 264 hour; n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.3533" spread="3.17528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Total (Urine+Feces), 264 to 288 hour; n=5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.158" spread="3.25412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Total (Urine+Feces), 288 to 312 hour; n=3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7300" spread="2.44851"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe Total (Urine+Feces), 312 to 336 hour; n=3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.9633" spread="2.16207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (0 to Inf) and AUC (0 to t) of Parent GSK2269557 and [14C]-GSK2269557 in Plasma for Treatment Period 1</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS, whereas GSK2269557 describes the parent GSK2269557 concentration derived via LC/MS. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.</description>
        <time_frame>Pre-dose and at 0 hour (post inhalation and pre-IV infusion), at the end of infusion and at 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours after the start of infusion</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Nemi IH + 14C-Nemi IV</title>
            <description>Participants received IV infusion of [14C] radiolabeled GSK2269557 as a single dose of 10 µg administered as single microtracer, concomitantly with an inhaled non-radiolabeled 1000 µg dose of GSK2269557.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0 to Inf) and AUC (0 to t) of Parent GSK2269557 and [14C]-GSK2269557 in Plasma for Treatment Period 1</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS, whereas GSK2269557 describes the parent GSK2269557 concentration derived via LC/MS. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.</description>
          <population>PK Population.</population>
          <units>Hour*picogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK2269557: AUC (0 to inf), n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33374.56" spread="33.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2269557: AUC (0 to t), n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28425.82" spread="34.474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>[14C]-GSK2269557: AUC (0 to inf), n=4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="750.5798" spread="48.27760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>[14C]-GSK2269557: AUC (0 to t), n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="546.4731" spread="45.31868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (0 to Inf) and AUC (0 to t) of [14C]-GSK2269557 in Plasma for Treatment Period 2</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. Only those participants with data available at the specified time points were analyzed represented by n=X in the category titles. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96 and 168 h post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>14C-Nemi Oral</title>
            <description>Participants received [14C]-GSK2269557 as a single dose of 800 µg, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0 to Inf) and AUC (0 to t) of [14C]-GSK2269557 in Plasma for Treatment Period 2</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. Only those participants with data available at the specified time points were analyzed represented by n=X in the category titles. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS.</description>
          <population>PK Population.</population>
          <units>Hour*picogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC (0 to inf), n=4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25107.96" spread="46.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0 to t), n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16913.06" spread="53.841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of Parent GSK2269557 and [14C]-GSK2269557 in Plasma for Treatment Period 1</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS, whereas GSK2269557 describes the parent GSK2269557 concentration derived via LC/MS.</description>
        <time_frame>Pre-dose and at 0 hour (post inhalation and pre-IV infusion), at the end of infusion and at 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours after the start of infusion</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Nemi IH + 14C-Nemi IV</title>
            <description>Participants received IV infusion of [14C] radiolabeled GSK2269557 as a single dose of 10 µg administered as single microtracer, concomitantly with an inhaled non-radiolabeled 1000 µg dose of GSK2269557.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Parent GSK2269557 and [14C]-GSK2269557 in Plasma for Treatment Period 1</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS, whereas GSK2269557 describes the parent GSK2269557 concentration derived via LC/MS.</description>
          <population>PK Population.</population>
          <units>Picograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK2269557</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5258.98" spread="62.819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>[14C]-GSK2269557</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205.6264" spread="57.91419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of [14C]-GSK2269557 in Plasma for Treatment Period 2</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96 and 168 h post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>14C-Nemi Oral</title>
            <description>Participants received [14C]-GSK2269557 as a single dose of 800 µg, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of [14C]-GSK2269557 in Plasma for Treatment Period 2</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS.</description>
          <population>PK Population.</population>
          <units>Picograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="398.8822" spread="27.81929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of Parent GSK2269557 and [14C]-GSK2269557 in Plasma for Treatment Period 1</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS, whereas GSK2269557 describes the parent GSK2269557 concentration derived via LC/MS.</description>
        <time_frame>Pre-dose and at 0 hour (post inhalation and pre-IV infusion), at the end of infusion and at 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours after the start of infusion</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Nemi IH + 14C-Nemi IV</title>
            <description>Participants received IV infusion of [14C] radiolabeled GSK2269557 as a single dose of 10 µg administered as single microtracer, concomitantly with an inhaled non-radiolabeled 1000 µg dose of GSK2269557.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Parent GSK2269557 and [14C]-GSK2269557 in Plasma for Treatment Period 1</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS, whereas GSK2269557 describes the parent GSK2269557 concentration derived via LC/MS.</description>
          <population>PK Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK2269557</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0333" lower_limit="0.017" upper_limit="0.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>[14C]-GSK2269557</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2333" lower_limit="0.2333" upper_limit="0.2333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of [14C]-GSK2269557 in Plasma for Treatment Period 2</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96 and 168 h post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>14C-Nemi Oral</title>
            <description>Participants received [14C]-GSK2269557 as a single dose of 800 µg, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of [14C]-GSK2269557 in Plasma for Treatment Period 2</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS.</description>
          <population>PK Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0000" lower_limit="2.000" upper_limit="8.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2 of Parent GSK2269557 and [14C]-GSK2269557 in Plasma for Treatment Period 1</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS, whereas GSK2269557 describes the parent GSK2269557 concentration derived via LC/MS. Only those participants available at the indicated time points were analyzed represented by n=X in the category titles.</description>
        <time_frame>Pre-dose and at 0 hour (post inhalation and pre-IV infusion), at the end of infusion and at 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours after the start of infusion</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Nemi IH + 14C-Nemi IV</title>
            <description>Participants received IV infusion of [14C] radiolabeled GSK2269557 as a single dose of 10 µg administered as single microtracer, concomitantly with an inhaled non-radiolabeled 1000 µg dose of GSK2269557.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of Parent GSK2269557 and [14C]-GSK2269557 in Plasma for Treatment Period 1</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS, whereas GSK2269557 describes the parent GSK2269557 concentration derived via LC/MS. Only those participants available at the indicated time points were analyzed represented by n=X in the category titles.</description>
          <population>PK Population.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK2269557</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.4408" spread="16.84150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>[14C]-GSK2269557</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.7223" spread="35.98970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2 of [14C]-GSK2269557 in Plasma for Treatment Period 2</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96 and 168 h post-dose</time_frame>
        <population>PK Population. Only those participants available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>14C-Nemi Oral</title>
            <description>Participants received [14C]-GSK2269557 as a single dose of 800 µg, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of [14C]-GSK2269557 in Plasma for Treatment Period 2</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS.</description>
          <population>PK Population. Only those participants available at the indicated time points were analyzed.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8028" spread="40.16665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution of Parent [14C]-GSK2269557 After IV Dose Only in Plasma</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS.</description>
        <time_frame>Pre-dose and at 0 hour (post inhalation and pre-IV infusion), at the end of infusion and at 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours after the start of infusion</time_frame>
        <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nemi IH + 14C-Nemi IV</title>
            <description>Participants received IV infusion of [14C] radiolabeled GSK2269557 as a single dose of 10 µg administered as single microtracer, concomitantly with an inhaled non-radiolabeled 1000 µg dose of GSK2269557.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution of Parent [14C]-GSK2269557 After IV Dose Only in Plasma</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS.</description>
          <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="727.7102" spread="11.24581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="851.4423" spread="13.98220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance of Parent [14C]-GSK2269557 After IV Dose Only in Plasma</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS.</description>
        <time_frame>Pre-dose and at 0 hour (post inhalation and pre-IV infusion), at the end of infusion and at 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours after the start of infusion</time_frame>
        <population>PK Population. Only those participants available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nemi IH + 14C-Nemi IV</title>
            <description>Participants received IV infusion of [14C] radiolabeled GSK2269557 as a single dose of 10 µg administered as single microtracer, concomitantly with an inhaled non-radiolabeled 1000 µg dose of GSK2269557.</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance of Parent [14C]-GSK2269557 After IV Dose Only in Plasma</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis. For measured concentrations of GSK2269557 in blood plasma, the nomenclature [14C]-GSK2269557 describes the parent GSK2269557 concentration derived via analysis by LC+AMS.</description>
          <population>PK Population. Only those participants available at the indicated time points were analyzed.</population>
          <units>Liters per hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7849" spread="46.70161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inhaled Absolute Bioavailability (F) for Treatment Period 1</title>
        <description>Absolute bioavailability (F) was estimated for the inhaled doses for each participant and is reported. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.</description>
        <time_frame>Pre-dose and at 0 hour (post inhalation and pre-IV infusion), at the end of infusion and at 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours after the start of infusion</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Nemi IH + 14C-Nemi IV</title>
            <description>Participants received IV infusion of [14C] radiolabeled GSK2269557 as a single dose of 10 µg administered as single microtracer, concomitantly with an inhaled non-radiolabeled 1000 µg dose of GSK2269557.</description>
          </group>
        </group_list>
        <measure>
          <title>Inhaled Absolute Bioavailability (F) for Treatment Period 1</title>
          <description>Absolute bioavailability (F) was estimated for the inhaled doses for each participant and is reported. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.</description>
          <population>PK Population.</population>
          <units>Fraction of drug</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inhaled F (0 to inf); n=4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3807" spread="19.65374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inhaled F (0 to t); n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4213" spread="21.84410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oral Absolute Bioavailability (F) for Treatment Period 2</title>
        <description>Absolute bioavailability (F) was estimated for the oral doses for each participant and is reported. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.</description>
        <time_frame>Pre-dose and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96 and 168 h post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>14C-Nemi Oral</title>
            <description>Participants received [14C]-GSK2269557 as a single dose of 800 µg, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Absolute Bioavailability (F) for Treatment Period 2</title>
          <description>Absolute bioavailability (F) was estimated for the oral doses for each participant and is reported. Only those participants available at the specified time points were analyzed represented by n=X in the category titles.</description>
          <population>PK Population.</population>
          <units>Fraction of drug</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oral F (0 to inf); n=4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3515" spread="3.35095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral F (0 to t); n=6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3261" spread="12.77892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)</title>
        <description>AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with use of a medicinal product (MP), whether or not considered related to MP. AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with use of MP. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant or all events of possible drug induced liver injury with hyperbilirubinemia.</description>
        <time_frame>Up to 11 weeks</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Nemi IH + 14C-Nemi IV</title>
            <description>Participants received IV infusion of [14C] radiolabeled GSK2269557 as a single dose of 10 µg administered as single microtracer, concomitantly with an inhaled non-radiolabeled 1000 µg dose of GSK2269557.</description>
          </group>
          <group group_id="O2">
            <title>14C-Nemi Oral</title>
            <description>Participants received solution of [14C] radiolabelled GSK2269557 as a single dose of 800 µg, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)</title>
          <description>AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with use of a medicinal product (MP), whether or not considered related to MP. AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with use of MP. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant or all events of possible drug induced liver injury with hyperbilirubinemia.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hematology Parameters of Potential Clinical Concern</title>
        <description>Hematology parameters included basophils, eosinophils, erythrocytes, monocytes, hematocrit, hemoglobin, lymphocytes, neutrophil count, platelet count and white blood cells. Number of participants with hematology parameters of potential clinical concern are presented.</description>
        <time_frame>Up to 11 weeks</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Nemi IH + 14C-Nemi IV</title>
            <description>Participants received IV infusion of [14C] radiolabeled GSK2269557 as a single dose of 10 µg administered as single microtracer, concomitantly with an inhaled non-radiolabeled 1000 µg dose of GSK2269557.</description>
          </group>
          <group group_id="O2">
            <title>14C-Nemi Oral</title>
            <description>Participants received solution of [14C] radiolabelled GSK2269557 as a single dose of 800 µg, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hematology Parameters of Potential Clinical Concern</title>
          <description>Hematology parameters included basophils, eosinophils, erythrocytes, monocytes, hematocrit, hemoglobin, lymphocytes, neutrophil count, platelet count and white blood cells. Number of participants with hematology parameters of potential clinical concern are presented.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Chemistry Parameters of Potential Clinical Concern</title>
        <description>Clinical chemistry parameters included alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, chloride, cholesterol, gamma glutamyl transferase, globulin, protein, triglycerides, urate, albumin, calcium, creatinine, glucose, phosphorous, potassium, urea and sodium. Number of participants with clinical chemistry parameters of potential clinical concern are presented.</description>
        <time_frame>Up to 11 weeks</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Nemi IH + 14C-Nemi IV</title>
            <description>Participants received IV infusion of [14C] radiolabeled GSK2269557 as a single dose of 10 µg administered as single microtracer, concomitantly with an inhaled non-radiolabeled 1000 µg dose of GSK2269557.</description>
          </group>
          <group group_id="O2">
            <title>14C-Nemi Oral</title>
            <description>Participants received solution of [14C] radiolabelled GSK2269557 as a single dose of 800 µg, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Chemistry Parameters of Potential Clinical Concern</title>
          <description>Clinical chemistry parameters included alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, chloride, cholesterol, gamma glutamyl transferase, globulin, protein, triglycerides, urate, albumin, calcium, creatinine, glucose, phosphorous, potassium, urea and sodium. Number of participants with clinical chemistry parameters of potential clinical concern are presented.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Urinalysis Findings</title>
        <description>Urine samples were collected to detect the presence of bilirubin, glucose, ketones, leukocyte esterase, nitrite, occult blood, protein and urobilinogen. Urinalysis also included measurement of specific gravity and pH. Number of participants with clinically significant urinalysis findings are presented.</description>
        <time_frame>Up to 168 hours</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Nemi IH + 14C-Nemi IV</title>
            <description>Participants received IV infusion of [14C] radiolabeled GSK2269557 as a single dose of 10 µg administered as single microtracer, concomitantly with an inhaled non-radiolabeled 1000 µg dose of GSK2269557.</description>
          </group>
          <group group_id="O2">
            <title>14C-Nemi Oral</title>
            <description>Participants received solution of [14C] radiolabelled GSK2269557 as a single dose of 800 µg, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Urinalysis Findings</title>
          <description>Urine samples were collected to detect the presence of bilirubin, glucose, ketones, leukocyte esterase, nitrite, occult blood, protein and urobilinogen. Urinalysis also included measurement of specific gravity and pH. Number of participants with clinically significant urinalysis findings are presented.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Electrocardiogram Findings of Clinical Significance</title>
        <description>Twelve-lead electrocardiogram was measured in a supine or semi-supine position after 5 minutes rest. Number of participants with electrocardiogram findings of clinical significance are presented.</description>
        <time_frame>Up to 11 weeks</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Nemi IH + 14C-Nemi IV</title>
            <description>Participants received IV infusion of [14C] radiolabeled GSK2269557 as a single dose of 10 µg administered as single microtracer, concomitantly with an inhaled non-radiolabeled 1000 µg dose of GSK2269557.</description>
          </group>
          <group group_id="O2">
            <title>14C-Nemi Oral</title>
            <description>Participants received solution of [14C] radiolabelled GSK2269557 as a single dose of 800 µg, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Electrocardiogram Findings of Clinical Significance</title>
          <description>Twelve-lead electrocardiogram was measured in a supine or semi-supine position after 5 minutes rest. Number of participants with electrocardiogram findings of clinical significance are presented.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Vital Signs of Potential Clinical Concern</title>
        <description>Vital signs were measured in a supine or semi-supine position after 5 minutes rest and included temperature, systolic and diastolic blood pressure and pulse and respiratory rate. Number of participants with vital signs of potential clinical concern are reported.</description>
        <time_frame>Up to 11 weeks</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Nemi IH + 14C-Nemi IV</title>
            <description>Participants received IV infusion of [14C] radiolabeled GSK2269557 as a single dose of 10 µg administered as single microtracer, concomitantly with an inhaled non-radiolabeled 1000 µg dose of GSK2269557.</description>
          </group>
          <group group_id="O2">
            <title>14C-Nemi Oral</title>
            <description>Participants received solution of [14C] radiolabelled GSK2269557 as a single dose of 800 µg, administered as an oral solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Signs of Potential Clinical Concern</title>
          <description>Vital signs were measured in a supine or semi-supine position after 5 minutes rest and included temperature, systolic and diastolic blood pressure and pulse and respiratory rate. Number of participants with vital signs of potential clinical concern are reported.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High respiratory rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious and non serious adverse events were evaluated up to 11 weeks</time_frame>
      <desc>Safety Population was analyzed to collect serious adverse events (SAE) and non-serious adverse events (nSAE).</desc>
      <group_list>
        <group group_id="E1">
          <title>Nemi IH + 14C-Nemi IV</title>
          <description>Participants received IV infusion of [14C] radiolabeled GSK2269557 as a single dose of 10 µg administered as single microtracer, concomitantly with an inhaled non-radiolabeled 1000 µg dose of GSK2269557.</description>
        </group>
        <group group_id="E2">
          <title>14C-Nemi Oral</title>
          <description>Participants received solution of [14C] radiolabelled GSK2269557 as a single dose of 800 µg orally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

